Agilent Technologies Signals Steady Growth Amid Headwinds

Agilent Technologies ((A)) has held its Q1 earnings call. Read on for the main highlights of the call.

Agilent Technologies’ latest earnings call struck a generally upbeat tone, with management emphasizing solid revenue growth, resilient margins and strong product momentum across key markets. Executives acknowledged pressure from tariffs, weather-related disruptions and softness in selective end markets, but stressed that Ignite-driven efficiencies and disciplined pricing should keep the company on its growth track.

Revenue Growth and Currency Tailwinds

Agilent posted Q1 revenue of $1.8 billion, translating into 4.4% core growth year over year and 7.0% reported growth. Currency was a meaningful factor, adding a 2.6% tailwind to reported results and underscoring how FX is currently working in the company’s favor.

Margins, Earnings and Updated EPS Outlook

Profitability held up, with non-GAAP operating margin at 24.6%, in line with expectations, and EPS rising about 4% to $1.36. Management kept the full-year core revenue growth outlook at 4%–6% and nudged the FY26 non-GAAP EPS range to $5.90–$6.04, reflecting FX upside.

Cash Generation, Capital Returns and Balance Sheet Strength

The company generated $268 million in operating cash flow in Q1 while spending $93 million on capex to support growth initiatives. Shareholders benefited from $152 million in buybacks and $72 million in dividends, and a net leverage ratio of 0.8x leaves ample room for further returns and M&A.

Ignite Operating System: Pricing Power and Efficiency

Agilent’s Ignite operating system delivered tangible financial gains, notably doubling pricing realization versus prior baselines and driving nearly 200 basis points of pricing last quarter. The program is also yielding procurement savings, organizational simplification, tariff mitigation and smoother integration of acquisitions such as BIOVECTRA.

Product Pipeline and Commercial Momentum

New products are fueling share gains, with the Infinity III HPLC platform driving high-single-digit LC growth and Pro iQ single-quad LC/MS systems expanding more than 40%. Altura columns helped push biocolumn growth above 30%, while Omnis expansion and the new S-540-MD Slide Scanner broadened Agilent’s clinical and diagnostics reach.

End-Market Strength in Pharma, CAM and Diagnostics

Pharma remained a standout, growing 7% with GLP-1-related revenue surging roughly 50% as that class of drugs scales globally. The chemicals and advanced materials segment rose 9%, aided by over 20% growth in advanced materials, while diagnostics and clinical revenue climbed 7% and instruments booked at or above 1 for the eighth straight quarter.

Specialty CDMO Growth and Integration Benefits

Agilent’s specialty CDMO business grew at a low double-digit rate in Q1, reinforcing its strategic role as a long-term growth driver. Management reiterated expectations for mid-teens growth this fiscal year and highlighted a successful, capability-enhancing integration of BIOVECTRA.

Enterprise Wins and New Contract Awards

The company continues to deepen its footprint with top-tier biopharma, as enterprise services now touch nearly all of the top-20 players. Agilent notched 18 competitive displacements over three years and secured a $9 million TSA contract for its Raman Insight BRT system in Q1, signaling strong competitive positioning.

Tariffs Weigh on Gross Margin

Tariff costs dragged Q1 gross margin down to 53.7%, about 100 basis points below last year, and also shaved around 50 basis points off operating margin. Management framed these as manageable headwinds, pointing to pricing, supply-chain localization and Ignite-driven efficiency as primary offsets.

Academic and Government Weakness

Academia and government spending was a soft spot, declining 8% in Q1 as U.S. academic customers prioritized operating budgets over new capital purchases. Agilent now expects this end market to fall in the low single digits for the year, tempering overall growth but remaining a contained drag.

Soft Pockets in Food, Environmental and LDG

Food testing revenue declined 4%, though performance looked better when excluding China, and environmental and forensics sales were essentially flat. Within Life Sciences & Diagnostics, LDG grew 3% but lagged internal expectations due to weaker demand in certain cell analysis and genomics niches.

Weather Disruption and Regional Impact

A late-January winter storm hit Agilent’s Americas logistics hub in Memphis, delaying roughly $10 million of revenue and limiting Americas growth to 1% in Q1. Most of that business shifted into early February, though some service revenue proved slower to recover, slightly distorting quarterly trends.

CDMO Margin Volatility from Batch Timing

While specialty CDMO revenue advanced at a low double-digit pace, margins were uneven due to batch cadence, which can swing profitability in any single quarter. Management indicated that such variability is inherent in the CDMO model and does not alter their confidence in the segment’s full-year trajectory.

Regional Dynamics and Macro Uncertainty

Europe grew about 4% but saw temporary pauses in purchasing as customers assessed tariff developments, showing how policy noise can influence buying behavior. China delivered 6% growth helped by modest pre–Lunar New Year spending and small stimulus effects, but management stressed that larger stimulus is still uncertain and not assumed in guidance.

Tariff Policy Risk and Mitigation Strategy

Ongoing tariff policy changes remain a key external risk, especially given recent rulings that may reshape cost structures. Agilent plans to counter these pressures with price increases, supply-chain localization and further Ignite savings, though management stressed that the situation remains fluid.

Guidance and Forward-Looking Outlook

Looking ahead, Agilent maintained its FY26 core revenue growth outlook of 4%–6%, translating to $7.3–$7.5 billion in reported revenue, and lifted EPS guidance to $5.90–$6.04 with FX as a modest tailwind. For Q2, the company is targeting 4%–5.5% core growth, revenue of $1.79–$1.82 billion, EPS of $1.39–$1.42, about 75 bps of full-year margin expansion and strong cash generation despite tariffs.

Agilent’s earnings call painted a picture of a company balancing solid execution with a realistic view of external risks, from tariffs to uneven funding. With healthy demand in pharma, diagnostics and advanced materials, robust new-product traction and Ignite-driven efficiency gains, management appears confident it can navigate near-term bumps while delivering steady growth and improving earnings power.